Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Treating HIV/HCV Coinfection

Source: Key Decisions in HIV Care
Listen as Mark S. Sulkowski, MD, shares the latest data and recommendations for treating HIV and HCV in patients who are coinfected, including considerations for HCV treatment as prevention and the impact of HCV treatment on the HIV care cascade.
Mark S. Sulkowski, MD
Released: February 16, 2022

In this episode, Mark S. Sulkowski, MD, explores recommendations and data on treating HIV and hepatitis C virus (HCV) in patients who are coinfected.

Listen as he gives his perspectives on:

  • Prioritization of both HIV and HCV treatment
  • Efficacy of HCV direct-acting antivirals in people with HIV
  • American Association for the Study of Liver Diseases/Infectious Diseases Society of America recommendations for first-line HCV treatment in HIV/HCV coinfection
  • International guidance on first-line antiretroviral therapy
  • HIV/HCV drug–drug interactions
  • The Swiss HCVree Trial of HCV treatment as prevention in men who have sex with men with HIV
  • Dependence of HCV elimination on the HIV care continuum for people who are HIV/HCV coinfected

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Information on this Educational Activity

Faculty

Mark S. Sulkowski, MD

Professor of Medicine
Medical Director, Viral Hepatitis Center
Chief, Infectious Disease
Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Mark S. Sulkowski, MD, has disclosed that he has received funds for research support from AbbVie, Assembly Bio, Gilead Sciences, and Janssen and consulting fees from AbbVie, Antios, Arbutus, Assembly Bio, Gilead Sciences, ViiV, and Virion.

Program Medium

This program has been made available online.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings